22. OVERVIEW OF CLINICAL TRIAL DESIGNS IN PRECISON ONCOLOGY
Main Article Content
Abstract
Objective: With advancements in next-generation sequencing technology, genomics, proteomics, and metabolomics have been increasingly applied in targeted cancer therapy. This review provides an overview of clinical trial design characteristics in precision medicine for physicians, researchers, and other stakeholders involved in the implementation of clinical trials. Additionally, we summarize the global landscape of clinical trials currently underway in precision oncology.
Methods: We searched PubMed from the inception until September 19, 2024 for eligible studies, which reported any clinical trial designs used in precision oncology and/or corresponding completed or on-going clinical trials.
Results: A “master protocol” framework was introduced to minimize participant exposure to ineffective drugs, accelerate dug development, and lower research costs. In 2018, the FDA issued the first draft guidance to expedite oncology drug development. Within this framework, basket trials test a targeted therapy across various cancers with the same molecular alteration, while umbrella trials assess multiple therapies within a single cancer, divided by molecular profiles. Platform trials provide a flexible design to evaluate multiple treatments simultaneously against a single control. Additionally, octopus trials, adaptive trials, telescope or seamless trials, N-of-1 trials designs have been also introduced. Among 34 identified precision oncology trials, 27 studies used basket, umbrella, and platform designs, which are main designs of the master protocol framework.
Conclusion: Drug efficacy assessment has gradually shifted to biomarker-guided trials, identifying many potential cancer therapies through basket, umbrella, and platform designs. Future trials may integrate technological and theoretical advancements to enhance personalized treatment and improve cancer management.
Article Details
Keywords
Study design, clinical trial, precision medicine, oncology
References
[2] Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14(1):101.
[3] National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease 2011. Available from: https://www.plengegen.com/wp-content/uploads/4_Toward-Precision-Medicine.pdf.
[4] Konig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017;50(4).
[5] Karlovich CA, Williams PM. Clinical applications of next-generation sequencing in precision oncology. Cancer J. 2019;25(4):264-71.
[6] Gibbs SN, Peneva D, Cuyun Carter G, Palomares MR, Thakkar S, Hall DW, et al. Comprehensive review on the clinical impact of next-generation sequencing tests for the management of advanced cancer. JCO Precis Oncol. 2023;7:e2200715.
[7] Novotech. Precision oncology clinical trials & statistics 2024 2024. Available from: https://novotech-cro.com/whitepapers/precision-oncology-clinical-trials-statistics-2024.
[8] Vadas A, Bilodeau TJ, Oza C. The evolution of biomarker use in clinical trials for cancer treatments 2018. Available from: https://www.lek.com/sites/default/files/insights/pdf-attachments/The_Evolution_of_Biomarker_Use_in_Clinical_Trials_for_Cancer_Treatments.pdf.
[9] BYT. Thông tư số 08/2022-TT-BYT quy định việc đăng ký lưu hành thuốc, nguyên liệu làm thuốc 2022. Available from: https://thuvienphapluat.vn/van-ban/The-thao-Y-te/Thong-tu-08-2022-TT-BYT-dang-ky-luu-hanh-thuoc-nguyen-lieu-lam-thuoc-528590.aspx.
[10] XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther. 2024;9(1):57.
[11] Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.
[12] Renfro LA, An MW, Mandrekar SJ. Precision oncology: a new era of cancer clinical trials. Cancer Lett. 2017;387:121-6.
[13] Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125-37.
[14] Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or doth. N Engl J Med. 2017;377(1):62-70.
[15] Redman MW, Allegra CJ. The master protocol concept. Semin Oncol. 2015;42(5):724-30.
[16] FDA. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and.